The Clinical Pharmacology of Cytosine Arabinoside
There is now little doubt that a proportion of patients with adult acute myelogenous leukaemia will achieve long-term survival and possibly cure with combination chemotherapy. Cytosine arabinoside (araC) is one of the most important drugs used in the treatment of this disease. Despite extensive clinical experience over the past 15 years, the schedule of administration remains controversial. These studies were conducted in an attempt to provide a greater understanding of the effect of both the schedule and route of administration on the clinical pharmacology of araC.
KeywordsAcute Myelogenous Leukaemia Cytosine Arabinoside Subcutaneous Infusion Venous Infusion Neoplastic Meningitis
Unable to display preview. Download preview PDF.
- 2.Canellos GD, Skarin AT, Ervin T, Weinstein H (1979) A chemotherapeutic approach to CNS lymphoma and leukaemia by the systemic administration of high dose of antimetabolites. In: Whitehouse JMA, Kay HEM (eds) CNS complications of malignant disease. pp 142–147Google Scholar
- 3.Early AP, Preisler HD, Slocum H, Rustum YM (to be published) A pilot study of high-dose cytosine arabinoside for acute leukaemia and refractory lymphoma. Clinical response and pharmacology. Cancer ResGoogle Scholar
- 5.Grossman S, Thompson G, Trump D (1981) Cerebrospinal fluid (CSF) flow abnormalities in patients with neoplastic meningitis (NM). Proc Am Soc Clin Oncol 22: 382Google Scholar
- 8.Karanes C, Wolfe SN, Herzig GP, Phillips GL, Lazarus HM, Herzig RH (1980) High-dose cytosine arabinoside (araC) in the treatment of patients with acute non-lymphocytic leukaemia (ANLL). Blood Abstr 504: 191 aGoogle Scholar
- 11.Rai KR, Glidewell O, Weinberg V, Holland JF (1981) Long-term remission in acute myelocytic leukaemia (AML): Report of a multi-institutional co-operative study. Proc Am Soc Clin 22: 481Google Scholar